← Leaderboards
Amanda Riley
Fred Hutchinson Cancer Center
$74,001
Attributed
$74,001
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $41.6K · FY2022–23$50K$37.5K$25K$12.5K$0
'22
'23
Funding mix
By agency
NIH$74,001 · 1
By mechanism
F31$74,001 · 1
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Toshio Tsukiyama$17,612,214
- Paul D Lampe$17,368,376
- Elizabeth Mary Swisher$14,985,539
- Marie Bleakley$9,428,742
- Denise A. Galloway$30,691,532
Others in their field
Other Rising Stars on “Adenocarcinoma Cell”
- Edwin Manuel · Beckman Research Institute/City Of Hope$3,382,655
- Reeder McNeil Robinson · Leukogene Therapeutics, Inc.$2,940,211
- Pingping Hou · Rutgers Biomedical And Health Sciences$2,730,524
- Evan Chen Lien · Massachusetts Institute Of Technology$2,399,497
- Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research$2,300,843
- Shumei Song · University Of Tx Md Anderson Can Ctr$2,178,114
Research focus
Adenocarcinoma CellAnchorage-Independent GrowthAutomobile DrivingAffectBindingBiochemistryBiologyCancer PatientCancer TherapyCareerCell GrowthCell ProliferationCellsCell SurvivalCessation Of LifeClinical TrialsCo-ImmunoprecipitationsCrispr ScreenCytotoxic ChemotherapyDeubiquitinationDriver MutationDruggable TargetDrug ResistanceEffective Therapy
Grant awards (2)
Elucidating how a USP9X-COP1 axis regulates RIT1 protein abundance and reveals druggable targets in lung adenocarcinoma$32,382
F31 · FY2023 · CA · contact PI
Elucidating how a USP9X-COP1 axis regulates RIT1 protein abundance and reveals druggable targets in lung adenocarcinoma$41,619
F31 · FY2022 · CA · contact PI